ClinicalTrials.gg
RecruitingNCT07284745Updated Nov 10, 2026

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

A Phase 3 interventional study of KarXT and KarX-EC in Irritability Associated With Autism Spectrum Disorder, sponsored by Bristol-Myers Squibb. Recruiting at 41 sites in 4 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
87th of 658
176 · median 50
Started
2026
with 46 others
Phase 3
25 of 773
6 open now
Primary completion
2029-08
later than 180 of 202 live
Registered
733rd of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 87th largest by planned enrollment of the 658 interventional ones that give a count, is one of 47 that started in 2026, is one of 25 in phase 3, reaches primary completion later than 180 of the 202 other live ones, and was the 733rd registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

159 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

03

Conditions studied

  • Irritability Associated With Autism Spectrum Disorder

Keywords

  • Cobenfy
  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of ASD, as defined by the , Fifth Edition, Text Revision (DSM-5-TR) criteria, confirmed by the K-SADS-PL and must be experiencing symptoms of irritability.
  • Participants must have ABC-I ≥18 (Irritability subscale of the ABC) and CGIS specific to irritability ≥4, at screening and baseline (Day 1).

Exclusion criteria

Exclusion Criteria

  • Participants must not have a current primary diagnosis of bipolar disorder, including bipolar II disorder, schizophrenia, schizoaffective disorder, major depressive episode as determined by clinical instrument, or post-traumatic stress disorder (PTSD).
  • Exception Include: Participants with comorbid ADHD, provided that attention deficit/hyperactivity disorder (ADHD) is not the primary disorder, the participant is adequately treated and based on the investigator judgment the disorder is clinically stable.
  • Participants must not have history/presence of disease or disorder that would jeopardize participant safety or validity of study results.
  • Participants must not have a risk for suicidal behavior, and any clinically significant abnormal laboratory test.
  • Other protocol-defined Inclusion/Exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    KarXT + KarX-EC Arm

    Drug: KarXT · Drug: KarX-EC

  • Placebo comparator
    Placebo

    Drug: KarXT + KarX-EC Matching Placebo

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510, Xanomeline/Trospium Chloride

  • Specified dose on specified days

    Also known as: BMS-986519, Xanomeline Enteric-coated

  • DrugKarXT + KarX-EC Matching Placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Aberrant Behavior Checklist Irritability (ABC-I) Score at Week 8

    Time frame: Week 8

Secondary outcomes

  1. Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Week 8

    Time frame: Week 8

  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 8

    Time frame: Week 8

  3. Number of Participants With ABC-I Response at Week 8

    Time frame: Week 8

  4. Change From Baseline on the ABC Subscale for Social Withdrawal at Week 8

    Time frame: Week 8

  5. Change From Baseline on the Stereotypic Behavior Subscale at Week 8

    Time frame: Week 8

  6. Change From Baseline on the Hyperactivity/Noncompliance Subscale at Week 8

    Time frame: Week 8

  7. Change From Baseline on the Inappropriate Speech Subscale at Week 8

    Time frame: Week 8

  8. Number of Participants With Procholinergic Symptoms

    Time frame: Up to approximately 12 weeks

  9. Number of Participants With Anticholinergic Symptoms

    Time frame: Up to approximately 12 weeks

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 12 weeks

  11. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to approximately 12 weeks

  12. Number of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: Up to approximately 12 weeks

  13. Number of Participants With AEs Leading to Discontinuation of Study Intervention

    Time frame: Up to approximately 8 weeks

  14. Plasma concentrations of KarXT

    Time frame: Up to approximately 8 weeks

07

Study locations

4 of 41 sites recruiting
  • Local Institution - 0036
    Dothan, Alabama 36303, United States
    Not yet recruiting
    • Site 0036 · Contact
  • Local Institution - 0236
    Phoenix, Arizona 85006, United States
    Not yet recruiting
    • Site 0236 · Contact
  • Local Institution - 0031
    Anaheim, California 92805, United States
    Not yet recruiting
    • Site 0031 · Contact
  • Cortica - Glendale
    Glendale, California 91203, United States
    Recruiting
    • Kevin Shapiro, Site 0257 · Contact747-286-2600
  • Local Institution - 0233
    Redlands, California 92373, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Cortica - Marin
    San Rafael, California 94903, United States
    Recruiting
    • Elysa Marco, Site 0181 · Contact415-572-4514
  • Local Institution - 0252
    Colorado Springs, Colorado 80910, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0264
    Boca Raton, Florida 33428, United States
    Not yet recruiting
    • Site 0264 · Contact
  • Local Institution - 0099
    Gainesville, Florida 32607, United States
    Not yet recruiting
    • Site 0099 · Contact
  • Local Institution - 0278
    Gainesville, Florida 32607, United States
    Not yet recruiting
    • Site 0278 · Contact
  • Local Institution - 0295
    Virginia Gardens, Florida 33166, United States
    Not yet recruiting
    • Site 0295 · Contact
  • Local Institution - 0155
    Peachtree Corners, Georgia 30071, United States
    Not yet recruiting
    • Site 0155 · Contact
  • EmVenio Research - Chicago
    Chicago, Illinois 60622, United States
    Recruiting
    • Mitchell Glaser, Site 0266 · Contact773-620-2995
  • Local Institution - 0242
    Louisville, Kentucky 40202, United States
    Not yet recruiting
    • Site 0242 · Contact
  • Local Institution - 0160
    Bloomfield Hills, Michigan 48302, United States
    Not yet recruiting
    • Site 0160 · Contact
  • Local Institution - 0110
    Las Vegas, Nevada 89128, United States
    Not yet recruiting
    • Site 0110 · Contact
  • Local Institution - 0290
    New York, New York 10016, United States
    Not yet recruiting
    • Site 0290 · Contact
  • Local Institution - 0246
    Staten Island, New York 10312, United States
    Not yet recruiting
    • Site 0246 · Contact
  • Local Institution - 0263
    The Bronx, New York 10461, United States
    Not yet recruiting
    • Site 0263 · Contact
  • Local Institution - 0122
    Cincinnati, Ohio 45229, United States
    Not yet recruiting
    • Site 0122 · Contact
  • Local Institution - 0247
    West Chester, Ohio 45069, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0269
    Danville, Pennsylvania 17821, United States
    Not yet recruiting
    • Site 0269 · Contact
  • Local Institution - 0292
    Nashville, Tennessee 37216, United States
    Not yet recruiting
    • Site 0292 · Contact
  • Local Institution - 0041
    Dallas, Texas 75243, United States
    Not yet recruiting
    • Site 0041 · Contact
  • Local Institution - 0034
    Houston, Texas 77090, United States
    Not yet recruiting
    • Site 0034 · Contact
  • Local Institution - 0273
    Plano, Texas 75093, United States
    Not yet recruiting
    • Site 0273 · Contact
  • Local Institution - 0291
    San Antonio, Texas 78249, United States
    Not yet recruiting
    • Site 0291 · Contact
  • Local Institution - 0185
    Spring, Texas 77381, United States
    Not yet recruiting
    • Site 0185 · Contact
  • Local Institution - 0294
    Orem, Utah 84097, United States
    Not yet recruiting
    • Site 0294 · Contact
  • Local Institution - 0293
    West Point, Utah 84015, United States
    Not yet recruiting
    • Site 0293 · Contact
  • Local Institution - 0260
    Richmond, Virginia 23220, United States
    Not yet recruiting
    • Site 0260 · Contact
  • Local Institution - 0010
    Westmead, New South Wales 2145, Australia
    Not yet recruiting
    • Site 0010 · Contact
  • Local Institution - 0007
    Brisbane, Queensland 4101, Australia
    Not yet recruiting
    • Site 0007 · Contact
  • Local Institution - 0045
    Melbourne, Victoria 3052, Australia
    Not yet recruiting
    • Site 0045 · Contact
  • Local Institution - 0286
    Melbourne, Victoria 3168, Australia
    Not yet recruiting
    • Site 0286 · Contact
  • Local Institution - 0289
    Airdrie, Alberta T4A 0K9, Canada
    Not yet recruiting
    • Site 0289 · Contact
  • Local Institution - 0136
    Edmonton, Alberta T6G 1Z1, Canada
    Not yet recruiting
    • Site 0136 · Contact
  • Local Institution - 0135
    Kingston, Ontario K7L4X3, Canada
    Not yet recruiting
    • Site 0135 · Contact
  • Local Institution - 0205
    Toronto, Ontario M4G 1R8, Canada
    Not yet recruiting
    • Site 0205 · Contact
  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
    Recruiting
    • Baudouin Forgeot D'Arc, Site 0187 · Contact
  • Local Institution - 0234
    San Juan, 00927, Puerto Rico
    Not yet recruiting
    • Site 0234 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2029, 34 months after the start.

Of 18 phase 3 interventional studies under Autism Spectrum Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 38. This study's planned 34 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Oct 6, 2026was Sep 2026
Primary completionEst.
Aug 6, 2029
CompletionEst.
Aug 6, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
9 sites added, 7 sites removed. 32 sites changed recruiting status (29 now not yet recruiting, 3 now withdrawn)
Show 32 sites
  • Local Institution - 0036 · Dothan, United Statesno status→Not yet recruiting
  • Local Institution - 0236 · Phoenix, United Statesno status→Not yet recruiting
  • Local Institution - 0031 · Anaheim, United Statesno status→Not yet recruiting
  • Local Institution - 0233 · Redlands, United Statesno status→Withdrawn
  • Local Institution - 0252 · Colorado Springs, United Statesno status→Withdrawn
  • Local Institution - 0264 · Boca Raton, United Statesno status→Not yet recruiting
  • Local Institution - 0099 · Gainesville, United Statesno status→Not yet recruiting
  • Local Institution - 0278 · Gainesville, United Statesno status→Not yet recruiting
  • Local Institution - 0155 · Peachtree Corners, United Statesno status→Not yet recruiting
  • Local Institution - 0242 · Louisville, United Statesno status→Not yet recruiting
  • Local Institution - 0160 · Bloomfield Hills, United Statesno status→Not yet recruiting
  • Local Institution - 0110 · Las Vegas, United Statesno status→Not yet recruiting
  • Local Institution - 0246 · Staten Island, United Statesno status→Not yet recruiting
  • Local Institution - 0263 · The Bronx, United Statesno status→Not yet recruiting
  • Local Institution - 0122 · Cincinnati, United Statesno status→Not yet recruiting
  • Local Institution - 0247 · West Chester, United Statesno status→Withdrawn
  • Local Institution - 0269 · Danville, United Statesno status→Not yet recruiting
  • Local Institution - 0041 · Dallas, United Statesno status→Not yet recruiting
  • Local Institution - 0034 · Houston, United Statesno status→Not yet recruiting
  • Local Institution - 0273 · Plano, United Statesno status→Not yet recruiting
  • Local Institution - 0291 · San Antonio, United Statesno status→Not yet recruiting
  • Local Institution - 0185 · Spring, United Statesno status→Not yet recruiting
  • Local Institution - 0260 · Richmond, United Statesno status→Not yet recruiting
  • Local Institution - 0010 · Westmead, Australiano status→Not yet recruiting
  • Local Institution - 0007 · Brisbane, Australiano status→Not yet recruiting
  • Local Institution - 0045 · Melbourne, Australiano status→Not yet recruiting
  • Local Institution - 0286 · Melbourne, Australiano status→Not yet recruiting
  • Local Institution - 0289 · Airdrie, Canadano status→Not yet recruiting
  • Local Institution - 0136 · Edmonton, Canadano status→Not yet recruiting
  • Local Institution - 0135 · Kingston, Canadano status→Not yet recruiting
  • …and 2 more on the registry record
Show 9 added (8 United States, 1 Canada)
  • Cortica - Glendale · Glendale, United States
  • Cortica - Marin · San Rafael, United States
  • Local Institution - 0295 · Virginia Gardens, United States
  • EmVenio Research - Chicago · Chicago, United States
  • Local Institution - 0290 · New York, United States
  • Local Institution - 0292 · Nashville, United States
  • Local Institution - 0294 · Orem, United States
  • Local Institution - 0293 · West Point, United States
  • CHU Sainte-Justine · Montreal, Canada
Show 7 removed
  • Local Institution - 0257 · Glendale, United States
  • Local Institution - 0181 · San Rafael, United States
  • Local Institution - 0266 · Chicago, United States
  • Local Institution - 0220 · Detroit, United States
  • Local Institution - 0074 · Bountiful, United States
  • Local Institution - 0271 · Provo, United States
  • Local Institution - 0187 · Montreal, Canada
Nov 10, 2026
Start date
Sep 11, 2026→Oct 6, 2026 (actual)
Nov 10, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNumber of Participants With ABC-I Response at Week 8: how it is measured was reworded
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Local Institution - 0233 · Redlands, United StatesContact removed (no phone or email listed)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    9 sites added, 7 sites removed. 32 sites changed recruiting status (29 now not yet recruiting, 3 now withdrawn)
    Show 32 sites
    • Local Institution - 0036 · Dothan, United Statesno status→Not yet recruiting
    • Local Institution - 0236 · Phoenix, United Statesno status→Not yet recruiting
    • Local Institution - 0031 · Anaheim, United Statesno status→Not yet recruiting
    • Local Institution - 0233 · Redlands, United Statesno status→Withdrawn
    • Local Institution - 0252 · Colorado Springs, United Statesno status→Withdrawn
    • Local Institution - 0264 · Boca Raton, United Statesno status→Not yet recruiting
    • Local Institution - 0099 · Gainesville, United Statesno status→Not yet recruiting
    • Local Institution - 0278 · Gainesville, United Statesno status→Not yet recruiting
    • Local Institution - 0155 · Peachtree Corners, United Statesno status→Not yet recruiting
    • Local Institution - 0242 · Louisville, United Statesno status→Not yet recruiting
    • Local Institution - 0160 · Bloomfield Hills, United Statesno status→Not yet recruiting
    • Local Institution - 0110 · Las Vegas, United Statesno status→Not yet recruiting
    • Local Institution - 0246 · Staten Island, United Statesno status→Not yet recruiting
    • Local Institution - 0263 · The Bronx, United Statesno status→Not yet recruiting
    • Local Institution - 0122 · Cincinnati, United Statesno status→Not yet recruiting
    • Local Institution - 0247 · West Chester, United Statesno status→Withdrawn
    • Local Institution - 0269 · Danville, United Statesno status→Not yet recruiting
    • Local Institution - 0041 · Dallas, United Statesno status→Not yet recruiting
    • Local Institution - 0034 · Houston, United Statesno status→Not yet recruiting
    • Local Institution - 0273 · Plano, United Statesno status→Not yet recruiting
    • Local Institution - 0291 · San Antonio, United Statesno status→Not yet recruiting
    • Local Institution - 0185 · Spring, United Statesno status→Not yet recruiting
    • Local Institution - 0260 · Richmond, United Statesno status→Not yet recruiting
    • Local Institution - 0010 · Westmead, Australiano status→Not yet recruiting
    • Local Institution - 0007 · Brisbane, Australiano status→Not yet recruiting
    • Local Institution - 0045 · Melbourne, Australiano status→Not yet recruiting
    • Local Institution - 0286 · Melbourne, Australiano status→Not yet recruiting
    • Local Institution - 0289 · Airdrie, Canadano status→Not yet recruiting
    • Local Institution - 0136 · Edmonton, Canadano status→Not yet recruiting
    • Local Institution - 0135 · Kingston, Canadano status→Not yet recruiting
    • …and 2 more on the registry record
    Show 9 added (8 United States, 1 Canada)
    • Cortica - Glendale · Glendale, United States
    • Cortica - Marin · San Rafael, United States
    • Local Institution - 0295 · Virginia Gardens, United States
    • EmVenio Research - Chicago · Chicago, United States
    • Local Institution - 0290 · New York, United States
    • Local Institution - 0292 · Nashville, United States
    • Local Institution - 0294 · Orem, United States
    • Local Institution - 0293 · West Point, United States
    • CHU Sainte-Justine · Montreal, Canada
    Show 7 removed
    • Local Institution - 0257 · Glendale, United States
    • Local Institution - 0181 · San Rafael, United States
    • Local Institution - 0266 · Chicago, United States
    • Local Institution - 0220 · Detroit, United States
    • Local Institution - 0074 · Bountiful, United States
    • Local Institution - 0271 · Provo, United States
    • Local Institution - 0187 · Montreal, Canada
    Start date Sep 11, 2026→Oct 6, 2026 (now actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of Participants With ABC-I Response at Week 8: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Local Institution - 0233 · Redlands, United StatesContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284745
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Oct 6, 2026
Primary completion
Aug 6, 2029 (estimated)
Completion
Aug 6, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion